[{"id":"e29e6931-dd47-4e5b-8bd2-f24887bb0bf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06116786","created_at":"2023-11-03T20:12:34.096Z","updated_at":"2025-02-25T14:18:28.129Z","phase":"Phase 1","brief_title":"A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06116786","lead_sponsor":"Johnson \u0026 Johnson Enterprise Innovation Inc.","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cetrelimab (JNJ-63723283)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 04/14/2027","primary_completion_date":" 04/14/2027","study_txt":" Completion: 06/07/2029","study_completion_date":" 06/07/2029","last_update_posted":"2025-02-17"},{"id":"4f8d5adb-a6bc-405c-b23e-5a23178d0926","acronym":"","url":"https://clinicaltrials.gov/study/NCT06534190","created_at":"2025-02-26T07:19:55.578Z","updated_at":"2025-02-26T07:19:55.578Z","phase":"Phase 2","brief_title":"CD8 PET Imaging in Metastatic Solid Tumours","source_id_and_acronym":"NCT06534190","lead_sponsor":"University Medical Center Groningen","biomarkers":" CD8","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cetrelimab (JNJ-63723283)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 11/01/2028","primary_completion_date":" 11/01/2028","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2024-12-13"},{"id":"ccfd455c-e774-4e0e-bb52-ee525cf236c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04592237","created_at":"2021-01-19T20:28:42.436Z","updated_at":"2024-07-02T16:34:58.883Z","phase":"Phase 2","brief_title":"Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04592237","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • TP53 • PTEN • RB1 • CEACAM5","pipe":" | ","alterations":" PTEN mutation","tags":["PD-L1 • TP53 • PTEN • RB1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Zejula (niraparib) • cabazitaxel • cetrelimab (JNJ-63723283)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/29/2020","start_date":" 12/29/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-04"},{"id":"ee1f7ecf-9bc4-4111-8b8a-fd3789290137","acronym":"","url":"https://clinicaltrials.gov/study/NCT04926181","created_at":"2021-06-15T17:53:11.788Z","updated_at":"2024-07-02T16:35:07.351Z","phase":"Phase 2","brief_title":"Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer","source_id_and_acronym":"NCT04926181","lead_sponsor":"Rahul Aggarwal","biomarkers":" RB1 • SYP","pipe":" | ","alterations":" RB1 deletion • RB1 mutation","tags":["RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • cetrelimab (JNJ-63723283)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-04-26"}]